FDA授予SRF388治疗肝癌的“快速通道资格”

2020-11-11 Allan MedSci原创

SRF388目前正在I期单一疗法剂量递增研究中招募晚期实体瘤患者,并计划进一步评估SRF388作为单一疗法以及与其他癌症疗法结合的有效性。

Surface Oncology是一家临床阶段的免疫肿瘤公司,致力于开发针对肿瘤微环境的下一代免疫疗法,今天宣布,美国食品药品监督管理局(FDA)已授予SRF388“快速通道资格”,用于治疗先前已经接受过标准疗法(例如血管内皮生长因子靶向药物和PD-L1阻断剂)治疗的肝细胞癌(HCC)患者。

在年初该药物提交IND,见:FDA批准SRF617(靶向CD39)和SRF388(靶向IL-27)的 IND

Surface Oncology首席医学官罗伯·罗斯说:“肝癌是美国男性和女性中增长最快的癌症类型,自1980年以来发病率增加了三倍,迫切需要新疗法来治疗肝癌。SRF388能够靶向IL-27(一种免疫抑制性细胞因子),IL-27已被发现在肝癌和肾癌患者中高表达。我们认为SRF388作为单药疗法有可能成为这些患者的有效治疗选择”。

SRF388目前正在I期单一疗法剂量递增研究中招募晚期实体瘤患者,并计划进一步评估SRF388作为单一疗法以及与其他癌症疗法结合的有效性。

 

原始出处:

https://www.firstwordpharma.com/node/1773183?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1981806, encodeId=7074198180661, content=<a href='/topic/show?id=fa7f16683c8' target=_blank style='color:#2F92EE;'>#SRF388#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16683, encryptionId=fa7f16683c8, topicName=SRF388)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7c9348, createdName=neizongke, createdTime=Wed Jan 13 11:31:37 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911373, encodeId=138d9113e359, content=快速通道资格, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 19:47:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911372, encodeId=ee359113e276, content=SRF388, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 19:47:43 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495280, encodeId=64631495280bb, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Fri Nov 13 14:31:37 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898628, encodeId=1733898628d8, content=靶向<a href='/topic/show?id=2dfe96581a' target=_blank style='color:#2F92EE;'>#IL-27#</a>用于<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>治疗,这是继<a href='/topic/show?id=4399103e93a7' target=_blank style='color:#2F92EE;'>#抗血管新生#</a>,<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>之后,又一新选择,以后几种方法组合,可能会对肝癌带来一些新的突破。 IL-27抑制剂主要是调节<a href='/topic/show?id=f0838291817' target=_blank style='color:#2F92EE;'>#肿瘤微环境#</a>的药物,可能会与PD-1类药物存在协同效应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=257, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9658, encryptionId=2dfe96581a, topicName=IL-27), TopicDto(id=81269, encryptionId=370d8126914, topicName=肝癌), TopicDto(id=103793, encryptionId=4399103e93a7, topicName=抗血管新生), TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=82918, encryptionId=f0838291817, topicName=肿瘤微环境)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:45:38 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040326, encodeId=b73910403262a, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Nov 12 02:31:37 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2021-01-13 neizongke
  2. [GetPortalCommentsPageByObjectIdResponse(id=1981806, encodeId=7074198180661, content=<a href='/topic/show?id=fa7f16683c8' target=_blank style='color:#2F92EE;'>#SRF388#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16683, encryptionId=fa7f16683c8, topicName=SRF388)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7c9348, createdName=neizongke, createdTime=Wed Jan 13 11:31:37 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911373, encodeId=138d9113e359, content=快速通道资格, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 19:47:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911372, encodeId=ee359113e276, content=SRF388, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 19:47:43 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495280, encodeId=64631495280bb, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Fri Nov 13 14:31:37 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898628, encodeId=1733898628d8, content=靶向<a href='/topic/show?id=2dfe96581a' target=_blank style='color:#2F92EE;'>#IL-27#</a>用于<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>治疗,这是继<a href='/topic/show?id=4399103e93a7' target=_blank style='color:#2F92EE;'>#抗血管新生#</a>,<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>之后,又一新选择,以后几种方法组合,可能会对肝癌带来一些新的突破。 IL-27抑制剂主要是调节<a href='/topic/show?id=f0838291817' target=_blank style='color:#2F92EE;'>#肿瘤微环境#</a>的药物,可能会与PD-1类药物存在协同效应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=257, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9658, encryptionId=2dfe96581a, topicName=IL-27), TopicDto(id=81269, encryptionId=370d8126914, topicName=肝癌), TopicDto(id=103793, encryptionId=4399103e93a7, topicName=抗血管新生), TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=82918, encryptionId=f0838291817, topicName=肿瘤微环境)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:45:38 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040326, encodeId=b73910403262a, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Nov 12 02:31:37 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2020-12-27 oo902

    快速通道资格

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1981806, encodeId=7074198180661, content=<a href='/topic/show?id=fa7f16683c8' target=_blank style='color:#2F92EE;'>#SRF388#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16683, encryptionId=fa7f16683c8, topicName=SRF388)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7c9348, createdName=neizongke, createdTime=Wed Jan 13 11:31:37 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911373, encodeId=138d9113e359, content=快速通道资格, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 19:47:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911372, encodeId=ee359113e276, content=SRF388, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 19:47:43 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495280, encodeId=64631495280bb, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Fri Nov 13 14:31:37 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898628, encodeId=1733898628d8, content=靶向<a href='/topic/show?id=2dfe96581a' target=_blank style='color:#2F92EE;'>#IL-27#</a>用于<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>治疗,这是继<a href='/topic/show?id=4399103e93a7' target=_blank style='color:#2F92EE;'>#抗血管新生#</a>,<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>之后,又一新选择,以后几种方法组合,可能会对肝癌带来一些新的突破。 IL-27抑制剂主要是调节<a href='/topic/show?id=f0838291817' target=_blank style='color:#2F92EE;'>#肿瘤微环境#</a>的药物,可能会与PD-1类药物存在协同效应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=257, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9658, encryptionId=2dfe96581a, topicName=IL-27), TopicDto(id=81269, encryptionId=370d8126914, topicName=肝癌), TopicDto(id=103793, encryptionId=4399103e93a7, topicName=抗血管新生), TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=82918, encryptionId=f0838291817, topicName=肿瘤微环境)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:45:38 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040326, encodeId=b73910403262a, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Nov 12 02:31:37 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2020-12-27 oo902

    SRF388

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1981806, encodeId=7074198180661, content=<a href='/topic/show?id=fa7f16683c8' target=_blank style='color:#2F92EE;'>#SRF388#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16683, encryptionId=fa7f16683c8, topicName=SRF388)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7c9348, createdName=neizongke, createdTime=Wed Jan 13 11:31:37 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911373, encodeId=138d9113e359, content=快速通道资格, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 19:47:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911372, encodeId=ee359113e276, content=SRF388, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 19:47:43 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495280, encodeId=64631495280bb, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Fri Nov 13 14:31:37 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898628, encodeId=1733898628d8, content=靶向<a href='/topic/show?id=2dfe96581a' target=_blank style='color:#2F92EE;'>#IL-27#</a>用于<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>治疗,这是继<a href='/topic/show?id=4399103e93a7' target=_blank style='color:#2F92EE;'>#抗血管新生#</a>,<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>之后,又一新选择,以后几种方法组合,可能会对肝癌带来一些新的突破。 IL-27抑制剂主要是调节<a href='/topic/show?id=f0838291817' target=_blank style='color:#2F92EE;'>#肿瘤微环境#</a>的药物,可能会与PD-1类药物存在协同效应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=257, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9658, encryptionId=2dfe96581a, topicName=IL-27), TopicDto(id=81269, encryptionId=370d8126914, topicName=肝癌), TopicDto(id=103793, encryptionId=4399103e93a7, topicName=抗血管新生), TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=82918, encryptionId=f0838291817, topicName=肿瘤微环境)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:45:38 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040326, encodeId=b73910403262a, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Nov 12 02:31:37 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1981806, encodeId=7074198180661, content=<a href='/topic/show?id=fa7f16683c8' target=_blank style='color:#2F92EE;'>#SRF388#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16683, encryptionId=fa7f16683c8, topicName=SRF388)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7c9348, createdName=neizongke, createdTime=Wed Jan 13 11:31:37 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911373, encodeId=138d9113e359, content=快速通道资格, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 19:47:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911372, encodeId=ee359113e276, content=SRF388, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 19:47:43 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495280, encodeId=64631495280bb, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Fri Nov 13 14:31:37 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898628, encodeId=1733898628d8, content=靶向<a href='/topic/show?id=2dfe96581a' target=_blank style='color:#2F92EE;'>#IL-27#</a>用于<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>治疗,这是继<a href='/topic/show?id=4399103e93a7' target=_blank style='color:#2F92EE;'>#抗血管新生#</a>,<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>之后,又一新选择,以后几种方法组合,可能会对肝癌带来一些新的突破。 IL-27抑制剂主要是调节<a href='/topic/show?id=f0838291817' target=_blank style='color:#2F92EE;'>#肿瘤微环境#</a>的药物,可能会与PD-1类药物存在协同效应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=257, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9658, encryptionId=2dfe96581a, topicName=IL-27), TopicDto(id=81269, encryptionId=370d8126914, topicName=肝癌), TopicDto(id=103793, encryptionId=4399103e93a7, topicName=抗血管新生), TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=82918, encryptionId=f0838291817, topicName=肿瘤微环境)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:45:38 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040326, encodeId=b73910403262a, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Nov 12 02:31:37 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2020-11-12 lovetcm

    靶向#IL-27#用于#肝癌#治疗,这是继#抗血管新生##免疫治疗#之后,又一新选择,以后几种方法组合,可能会对肝癌带来一些新的突破。 IL-27抑制剂主要是调节#肿瘤微环境#的药物,可能会与PD-1类药物存在协同效应。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1981806, encodeId=7074198180661, content=<a href='/topic/show?id=fa7f16683c8' target=_blank style='color:#2F92EE;'>#SRF388#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16683, encryptionId=fa7f16683c8, topicName=SRF388)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7c9348, createdName=neizongke, createdTime=Wed Jan 13 11:31:37 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911373, encodeId=138d9113e359, content=快速通道资格, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 19:47:49 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911372, encodeId=ee359113e276, content=SRF388, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 19:47:43 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495280, encodeId=64631495280bb, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Fri Nov 13 14:31:37 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898628, encodeId=1733898628d8, content=靶向<a href='/topic/show?id=2dfe96581a' target=_blank style='color:#2F92EE;'>#IL-27#</a>用于<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>治疗,这是继<a href='/topic/show?id=4399103e93a7' target=_blank style='color:#2F92EE;'>#抗血管新生#</a>,<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>之后,又一新选择,以后几种方法组合,可能会对肝癌带来一些新的突破。 IL-27抑制剂主要是调节<a href='/topic/show?id=f0838291817' target=_blank style='color:#2F92EE;'>#肿瘤微环境#</a>的药物,可能会与PD-1类药物存在协同效应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=257, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9658, encryptionId=2dfe96581a, topicName=IL-27), TopicDto(id=81269, encryptionId=370d8126914, topicName=肝癌), TopicDto(id=103793, encryptionId=4399103e93a7, topicName=抗血管新生), TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=82918, encryptionId=f0838291817, topicName=肿瘤微环境)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:45:38 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040326, encodeId=b73910403262a, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Nov 12 02:31:37 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2020-11-12 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0

相关资讯

FDA正式批准新冠药物瑞德西韦

美东时间10月22日,美国FDA正式批准吉利德抗病毒药物Veklury(remdesivir,瑞德西韦)上市,用于12岁及以上、体重至少40公斤的需要住院治疗的成人和儿童COVID-19治疗。FDA新

2020年1-10月FDA批准的41款新药,信息大汇总

当提到新药和治疗性生物产品的开发创新时,FDA的药物评估和研究中心(CDER)在这个过程的每一步都为制药业提供支持。凭借其对用于创造新产品的科学、测试和制造过程以及新产品旨在治疗的疾病和条件的了解,C

早期肺癌辅助治疗!奥希替尼新适应症上市申请获FDA优先审评资格

阿斯利康宣布FDA接受其提交的奥希替尼补充新药申请(sNDA),并授予优先审评资格,用于对接受过完全肿瘤切除术的早期(IB、II和IIIA期)表皮生长因子受体突变(EGFRm)非小细胞肺癌(NSCLC

美国FDA批准欧狄沃联合伊匹木单抗用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者,成为且目前**获批的免疫疗法

美国食品药品监督管理局(FDA)已批准欧狄沃(360mg,每3周一次)联合伊匹木单抗(1mg/kg,每6周一次)用于一线治疗不可切除的恶性胸膜间皮瘤(MPM)成人患者。该批准是基于III期临床研究Ch

FDA批准候选药物lanifibranor进入III期临床,以治疗非酒精性脂肪性肝炎(NASH)

生物制药公司Inventiva致力于开发口服小分子疗法,用于治疗非酒精性脂肪性肝炎(NASH)。

BMJ:新药快速审批通道与临床治疗价值

在过去十年中,FDA和EMA批准的新药中,不到三分之一被认为具有较高的治疗价值,但两大医药监管部门对新药授予快速审批资格标准具有一定差异,多数经FDA批准但非EMA批准的加急药物被认为治疗价值较低

拓展阅读

FDA批准SRF617(靶向CD39)和SRF388(靶向IL-27)的 IND

Surface Oncology是一家临床阶段的免疫肿瘤学公司,致力于开发针对肿瘤微环境的下一代免疫疗法,近日宣布,美国FDA已批准候选抗体SRF617(靶向CD39)和SRF388(靶向IL-27)的研究性新药(IND)申请,该公司正在启动I期临床试验。